Indications/Uses
Acute attack of chloroquine-resistant falciparum malaria.
|
Dosage/Direction for Use
Adult: PO Per tab contains sulfadoxine 500 mg and pyrimethamine 25 mg: 2-3 tabs as a single dose. Do not repeat w/in 7 days.
|
Contraindications
Severe renal or hepatic impairment, blood dyscrasias, hypersensitivity to components, megaloblastic anaemia due to folate deficiency, pregnancy at term and during lactation, infants ≤ 2 mth old.
|
Special Precautions
Impaired renal or hepatic function, folate deficiency, severe allergy or bronchial asthma, G6PD deficiency, pregnancy. Take with plenty of water to prevent crystalluria. Avoid excessive exposure to sun. Discontinue at the first sign of rash. Discontinue if signs of folic acid deficiency develops. Regular CBC monitoring, LFT, analysis of urine for crystalluria when admin for > 3 mth. Take with food to minimise Gi effects (e.g. anorexia and vomiting).
|
Adverse Reactions
Urticaria, serum sickness, photosensitisation, arthralgia, nausea, vomiting, abdominal pain, diarrhoea, headache, peripheral neuritis, ataxia, tinnitus, vertigo, convulsions, toxic nephrosis and pulmonary infiltrates resembling eosinophilic or allergic alveolitis.
Potentially Fatal: Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, blood dyscrasias, anaphylactoid reactions. |
Drug Interactions
Increased halofantrine and chlorpromazine levels. Increased effects of warfarin.
|
CIMS Class
|
ATC Classification
P01BD01 - pyrimethamine ; Belongs to the class of diaminopyrimidine antimalarials.
|